SCHEMBL391666

SCHEMBL391666

Cc1cnc(F)cc1-c1cccc2ccsc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2B6 P20813 2/20 0.38
CYP2C19 P33261 2/20 0.38
DRD1 P21728 2/20 0.37
ATR Q13535 1/20 0.36
PLA2G7 Q13093 2/20 0.33
ADRB2 P07550 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRB1 P08588 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD2 P14416 1/20 0.33
CHRM3 P20309 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
HRH2 P25021 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338523 0.81 ATR (0.35) CYP2A6DRD1ATRADRB2CHRM2
SCHEMBL2874415 0.78 MAP3K7 (0.34) CYP2A6DRD1ATRADRB2CHRM2
SCHEMBL4439252 0.77 ATR (0.37) CYP2A6DRD1ATRADRB2CHRM2
SCHEMBL595134 0.77 ADRB2 (0.35) DRD1ATRADRB2CHRM2ADRB1
SCHEMBL594957 0.77 ADRB2 (0.33) DRD1ATRADRB2CHRM2ADRB1
SCHEMBL13863788 0.75 CYP2A6 (0.39) CYP2A6DRD1ATRPLA2G7HTR2A
SCHEMBL2876929 0.75 ATR (0.34) CYP2A6DRD1ATRADRB2CHRM2
SCHEMBL14831141 0.75 CYP17A1 (0.43) CYP2A6CYP3A4CYP2C19DRD1ATR
SCHEMBL17124466 0.74 CYP2A6 (0.43) CYP2A6CYP3A4ATRPLA2G7SLC6A3
SCHEMBL14830903 0.73 CYP17A1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114872-B2 Triazolyl aminopyrimidine compounds ELI LILLY AND COMPANY (US) 2012-02-14 US disclosed
US-8101628-B2 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer ELI LILLY AND COMPANY (US) 2012-01-24 US disclosed
EP-2125793-B1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2010-09-01 EP disclosed
US-20100130466-A1 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS ELI LILLY AND COMPANY 2010-05-27 US disclosed
US-20100076001-A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER ELI LILLY AND COMPANY 2010-03-25 US disclosed
EP-2155735-A2 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2010-02-24 EP disclosed
WO-2008144222-A2 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076001-A1 IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER PLK1, BUB1B, BUB1 CYP2A6 4648/4885CYP3A4 4367/4885CYP2B6 4488/4885
US-20100130466-A1 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS DPYD, TP53, TYMP CYP2A6 1744/4885CYP3A4 586/4885CYP2B6 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.